Feasibility Study: Heavy Water Tissue Labeling Protocol
Status: | Completed |
---|---|
Conditions: | Dermatology |
Therapuetic Areas: | Dermatology / Plastic Surgery |
Healthy: | No |
Age Range: | 30 - 65 |
Updated: | 12/13/2017 |
Start Date: | August 2012 |
End Date: | November 2013 |
Feasibility Study: Determination of the Effect of Ultherapy® Treatment on the Rate of Collagen Synthesis in Normal Skin
Enrolled subjects undergo tissue labeling to evaluate the rate of collagen synthesis in
tissue treated with the Ulthera® System compared to control tissue.
tissue treated with the Ulthera® System compared to control tissue.
This study is a prospective, single-center, blinded, non-randomized clinical trial. Two
subjects who have chosen to have a surgical facelift procedure and agree to drink heavy water
for tissue labeling, will be enrolled. Subjects will consume heavy water and collect saliva
specimens over the course of the study period, following a specific heavy water labeling
protocol. Two weeks after starting the heavy water protocol, subjects will return to the
study site to receive one Ultherapy® treatment to the pre-auricular region on one side of the
face. The contra-lateral pre-auricular region will serve as a control. Following Ultherapy®
treatment, subjects will continue to follow the heavy water protocol for 4 more weeks.
Subjects will then return to the study site to undergo resection of the treated and control
tissue for analysis during their planned rhytidectomy procedure. Subjects will send in saliva
samples on a weekly basis to allow for confirmation that they are drinking the heavy water.
subjects who have chosen to have a surgical facelift procedure and agree to drink heavy water
for tissue labeling, will be enrolled. Subjects will consume heavy water and collect saliva
specimens over the course of the study period, following a specific heavy water labeling
protocol. Two weeks after starting the heavy water protocol, subjects will return to the
study site to receive one Ultherapy® treatment to the pre-auricular region on one side of the
face. The contra-lateral pre-auricular region will serve as a control. Following Ultherapy®
treatment, subjects will continue to follow the heavy water protocol for 4 more weeks.
Subjects will then return to the study site to undergo resection of the treated and control
tissue for analysis during their planned rhytidectomy procedure. Subjects will send in saliva
samples on a weekly basis to allow for confirmation that they are drinking the heavy water.
Inclusion Criteria:
- Male or female, age 30 to 65 years scheduled for rhytidectomy.
- Subject in good health.
- Understands and accepts the obligation not to undergo any other procedures in the
areas to be treated.
- Willingness and ability to comply with protocol requirements, including returning for
follow-up visits and abstaining from exclusionary procedures for the duration of the
study.
- Subjects of childbearing potential must have a negative urine pregnancy test result
and must not be lactating at Visit 1 and be willing and able to use an acceptable
method of birth control.
- Absence of physical or psychological conditions unacceptable to the investigator.
- Willingness and ability to provide written consent for study-required photography and
adherence to photography procedures (i.e., removal of jewelry and makeup).
- Willingness and ability to provide written informed consent and HIPAA authorization
prior to performance of any study-related procedure.
Exclusion Criteria:
- Presence of an active systemic or local skin disease that may affect wound healing.
- Severe solar elastosis.
- Significant scarring in areas to be treated.
- Open wounds or lesions in the area to be treated.
- Severe or cystic acne on the area to be treated.
- Presence of a metal stent or implant in the facial area to be treated.
- Inability to understand the protocol or to give informed consent.
- Microdermabrasion, or prescription level glycolic acid treatments to the submental
area within two weeks prior to study participation or during the study.
- Excessive dermatochalasis, deep dermal scarring, or thick sebaceous skin in the area
to be treated.
- BMI equal to or greater than 30.
We found this trial at
1
site
Click here to add this to my saved trials